Several novel 15-membered-ring macrolide agents (azalide 1, triamilides 2 and 3, and the azalide 3,6-ketal 4) were identified as potential antibacterial agents against Mannheimia (formerly named as Pasteurella) haemolytica, Pasteurella multocida, Haemophilus somnus and Actinobacillus pleuropneumoniae, important etiological agents of bovine and porcine respiratory disease. Compound 3 is the major component of the antibiotic tulathromycin. Antibacterial activity against tilmicosin-resistant P. multocida field isolates was also tested. In vitro MIC 50/90 analysis revealed that the four newly synthesized compounds were more potent kinetic studies, all four novel compounds and tilmicosin showed bactericidal activity against M.
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assay using genetically defined mutants revealed that all four novel compounds were poorer substrates for the efflux pump, AcrA/B system, than tilmicosin. A pH study using LPS mutants indicated that the enhanced in vitro potency of the triamilides, particularly compound 3 was mainly due to better penetration of the molecule through the outer membrane. The third amine group at the C-4" position of the triamilde molecules contributed to this increased membrane penetration by increasing overall basicity. These studies indicate that the four novel compounds have potential as antibacterial agents against bovine and porcine respiratory disease.
Bovine respiratory disease (BRD, shipping fever)
continues to be a primary cause of morbidity and mortality in feedlot production. 300CFU/ml20).
Results

Antibacterial Activities
The four novel compounds, azalide 1, triamilides 2 and 3, and azalide 3,6-ketal 4 were analyzed for their antibacterial activity against a collection of Gram-negative animal respiratory pathogens which included reference ATCC strains and a panel of field isolates (see Table 1 -A).
All four compounds showed improved in vitro antibacterial activity against these pathogens compared to tilmicosin.
The MIC 50/90 values for compounds 1, 2, 3, and 4 against major livestock respiratory pathogens, M. haemolytica (bovine), P. multocida (bovine and swine), A. pleuropneumoniae (swine), and H. somnus (bovine), suggested that they were four or more times more potent than tilmicosin (Table 1-A) . In particular, all four novel compounds showed good activity against tilmicosinresistant P. multocida field isolates (the breakpoint of these guidelines16)). There was no noticeable difference among MIC 50/90s of all four compounds against M. haemolytica, P. multocida, and A. pleuropneumoniae. However, azalide 1 presented in Fig. 2 . All five compounds showed bactericidal activity against A, pleuropneumoniae, M, haemolytica, and P. multocida after 24-hour incubation. All five compounds effectively killed M. haemolytica during an initial 3-hour incubation and there was no re-growth during the following 21-hour incubation in the presence of these antibiotics.
The kill-kinetics of compounds 1, 2, and 3 for A. pleuropneumoniae were identical to those for M. haemolytica. The kill-kinetics of tilmicosin and compound 4, however, were slightly different. Both compounds needed an additional 3 hours (total drug exposure=6 hours) to kill A. pleuropneumoniae under the assay detection limits. In contrast, P. multocida was gradually killed during the 24-hour drug exposure. At early time points (3 and 6 hours), bacterial cell numbers were reduced only one to one and a half log10. Among the compounds tested, compound 3 showed better killing kinetics at early time points. All compounds showed bactericidal activity after 24-hour incubation. The results of the cell-free transcription/translation assay with macrolide-sensitive and macrolide-resistant ribosomes are presented in Table 2 . All four macrolides (erythromycin A, azithromycin, compound 3, and tilmicosin) showed (Table 2 ).
Outer Membrane Penetration of Macrolides
The in vitro potency of the tri-basic triamilide, compound 3 was further analyzed by pH assays using genetically defined LPS mutants to assess its bacterial outer membrane penetration ability, compared to the control agents, erythromycin A (mono-basic) and azithromycin (dibasic). In these experiments, pH change (acidic, neutral, and alkaline) was used as a tool to control ionized and neutral moieties of test molecules based on each compound's pKa. The pKa values of erythromycin A, azithromycin, and compound 3 are shown in Fig. 1 . These values are already published14) or obtained from a contract research laboratory24). The MIC results are presented in Table 3 . A simplified LPS structure, the LPS mutation phenotype, and the corresponding mutant strain numbers are presented in Fig. 33 ).
The activities of the test macrolides were affected by the pH of the test medium; their potencies were significantly improved in alkaline conditions. With pH changes from acidic (pH 6.0) to alkaline (pH 8.0) conditions, the potency (MIC) of erythromycin A against the wild-type smooth LPS strain (SA 1355) increased 43-fold (MIC decreased alkaline pH was observed in Ra and Rd2 LPS mutants (Table 3) . LPS structural changes due to mutation also affected in vitro potency. The susceptibility patterns of the Ra mutant to erythromycin A, azithromycin, and compound 3 were identical to those of the smooth wild-type strain. All three compounds, however, showed improved potency against the deep-rough mutant, Rd2. At acidic conditions (pH 6.0), there was a minor improvement (2-to 3-fold) in the potency of azithromycin and compound 3. In contrast, erythromycin A was 8 times more potent against the deeprough mutant than the smooth wild-type and Ra mutant strains. At alkaline conditions (pH 8.0), both erythromycin A and azithromycin were 24 times more potent against Rd2 compared to the smooth wild-type strain. Compound 3, however, showed only a 4.5-fold improved potency against the Rd2 strain compared to the wild-type smooth strain.
Discussion
The antibacterial activities against ATCC strains and MIC 50/90 analysis with field isolates indicate that the novel compounds azalide 1, triamilides 2 and 3, and azalide 3,6-ketal 4 are generally more potent against Gramnegative respiratory pathogens than tilmicosin, a drug frequently used in the treatment of BRD. The MIC 50/90s of all four novel antibiotics against major target pathogens of BRD (M. haemolytica and P. multocida) and SRD (P. multocida and A. pleuropneumoniae) were 4 to 16 times lower than those of tilmicosin (Table 1-A). All four novel compounds also showed good in vitro activity against tilmicosin-resistant P. multocida field isolates. Kill-kinetic studies indicated that all four novel compounds were equivalent to (compound 4) or better than the comparator agent, tilmicosin, against M. haemolytica, P. multocida, and A. pleuropneumoniae.
In addition, the newly synthesized macrolides were poor substrates of the efflux pump AcrA/B (particularly azalide 1 and triamilides 2 and 3). Many antibiotics, including macrolides (erythromycin A) and novobiocin, are known to be effectively pumped out of E. coli cells by this efflux system4,13), which contributes to significantly higher MICs.
Recently, the existence of AcrA/B in S. typhimurium17,21) and its homologue in Haemophilus influenzae23) was reported. These results indicate a wide distribution of the AcrA/B efflux pump system among Gram-negative bacteria.
In the present study, there was a 256-fold differential novobiocin (Table 1-B) . In contrast, tilmicosin showed only a 16-fold differential. This result indicates that tilmicosin is also a relatively poor substrate of this system. The azalide and triamilides, however, showed much lower affinity to the AcrA/B efflux pump system (2-fold differential) compared to tilmicosin. The significantly reduced efflux pump affinity, improved potency, and excellent kill-kinetics, suggest that the newly synthesized macrolides may have a significant advantages in treating livestock respiratory disease.
The results obtained here with the LPS mutant Salmonella strains raised interesting questions concerning Table 3 . Effect of pH and LPS mutations on in vitro activity of erythromycin A (mono-basic 14-membered ring), azithromycin (di-basic 15-membered-ring) and triamilide, compound 3 (tri-basic 15-membered-ring). (Table 3 , pH 6.0). The basic amine groups of erythromycin A, azithromycin, and triamilide compound 3 are completely ionized at acidic conditions and are positively charged. In contrast, at neutral and alkaline pH, these amines are partially ionized and are less positively charged. The degree of neutralization depends on their dissociation constants (pKa). The fully positively-charged-amines in acidic conditions should give all three molecules an advantage as LPS disturbing agents over those partially charged amines under neutral and alkaline conditions. However, all three compounds were inactive at pH 6.0. This discrepancy may be explained by considering lipid solubility. It is well described in the literature's that "the un-ionized form is usually more lipidsoluble and can more easily diffuse across the cell membrane. In contrast, the ionized moiety is often virtually excluded from transmembrane diffusion because of its low lipid solubility". All three macrolides are fully ionized at pH 6.0, which maximizes their function as LPS disturbing agents, but minimizes their ability to pass through the outer and inner membranes due to their lipid insolubility. Therefore, those macrolides cannot reach their molecular target, the ribosomes. In alkaline conditions (pH 8.0), the percentage of neutralized molecules increases and these can reach the target by passing through the outer and inner membranes. However, the molecule's activities as an LPS disturbing agent, as observed in acidic conditions, are diminished. At neutral to physiological pH, the MICs observed are the result of the balance between LPS disturbing activity (positively charged residues) and lipid soluble transmembrane activity (neutral residue). In the deep rough mutant, the LPS permeability barrier is already eliminated and we mainly observe the lipid soluble transmembrane activity (and intrinsic protein synthesis activity). In this pH range, azithromycin is less ionized than compound 3, which results in azithromycin's superior activity (Table 3) . In contrast to azithromycin and compound 3, erythromycin A contains only one amine group on desosamine and its pKa1 is 8.8. Although the majority of this amine is also ionized at pH 8, the single charged amine residue of erythromycin A lacks the effective outer membrane disturbing activity. Such membrane disturbing activity requires at least two positively charged groups around the macrolide lactone-ring. Therefore, erythromycin A is less effective at penetrating the outer membrane than the azalides and the triamilides. Our cell free transcription/translation inhibition assay indicated that the intrinsic activities of all three macrolides as protein synthesis inhibitors were practically identical (particularly between azithromycin and compound 3). Therefore, the observed improved potency of compound 3 compared to azithromycin against the wild-type strain is probably caused by the different LPS disturbing activity of each molecule.
The pKa3 of the third amine on cladinose (not present in azithromycin) is 9.9. The majority of these amine sites are still positively charged at neutral-physiological pH which can fully interact with Mg2+ binding sites of LPS, together with the other positively charged NH group of the lactonering (pKa2, 9.62). This unique nature of the third amine clearly differentiates triamildes from other macrolide antibiotics.
